CN1020903C - 新颖的(1h-咪唑-1-基甲基)取代的苯并咪唑衍生物的制备方法 - Google Patents

新颖的(1h-咪唑-1-基甲基)取代的苯并咪唑衍生物的制备方法 Download PDF

Info

Publication number
CN1020903C
CN1020903C CN87106423A CN87106423A CN1020903C CN 1020903 C CN1020903 C CN 1020903C CN 87106423 A CN87106423 A CN 87106423A CN 87106423 A CN87106423 A CN 87106423A CN 1020903 C CN1020903 C CN 1020903C
Authority
CN
China
Prior art keywords
parts
formula
imidazoles
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN87106423A
Other languages
English (en)
Chinese (zh)
Other versions
CN87106423A (zh
Inventor
阿方斯·赫尔曼·玛加理莎·拉马克斯
埃迪·让·埃德加德·弗雷
杰勒德·查尔斯·桑斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN87106423A publication Critical patent/CN87106423A/zh
Application granted granted Critical
Publication of CN1020903C publication Critical patent/CN1020903C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN87106423A 1986-09-15 1987-09-15 新颖的(1h-咪唑-1-基甲基)取代的苯并咪唑衍生物的制备方法 Expired - Lifetime CN1020903C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90790386A 1986-09-15 1986-09-15
US907,903 1986-09-15

Publications (2)

Publication Number Publication Date
CN87106423A CN87106423A (zh) 1988-04-20
CN1020903C true CN1020903C (zh) 1993-05-26

Family

ID=25424835

Family Applications (1)

Application Number Title Priority Date Filing Date
CN87106423A Expired - Lifetime CN1020903C (zh) 1986-09-15 1987-09-15 新颖的(1h-咪唑-1-基甲基)取代的苯并咪唑衍生物的制备方法

Country Status (23)

Country Link
EP (1) EP0260744B1 (enExample)
JP (1) JPS6485975A (enExample)
KR (1) KR960014353B1 (enExample)
CN (1) CN1020903C (enExample)
AU (1) AU595064B2 (enExample)
BG (1) BG61321B2 (enExample)
CA (1) CA1323366C (enExample)
CY (1) CY1803A (enExample)
DE (1) DE3783107T2 (enExample)
DK (1) DK174728B1 (enExample)
ES (1) ES2053524T3 (enExample)
FI (1) FI87781C (enExample)
GR (1) GR3006841T3 (enExample)
HK (1) HK123694A (enExample)
HU (1) HU198039B (enExample)
IE (1) IE60514B1 (enExample)
IL (1) IL83892A (enExample)
NO (1) NO167202C (enExample)
NZ (1) NZ221729A (enExample)
PH (1) PH25022A (enExample)
PT (1) PT85692B (enExample)
SU (1) SU1662350A3 (enExample)
ZA (1) ZA876881B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100496308C (zh) * 2006-06-02 2009-06-10 上海烟草（集团）公司 造纸法再造烟叶半逆流多级萃取工艺

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826862A (en) * 1988-02-12 1989-05-02 Janssen Pharmaceutica, N.V. Anthelminthic [(5(6) (1H-azole-1-ylmethyl)benzimidazole]carbamates
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
FR2643903A1 (fr) * 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
US5021448A (en) * 1990-02-22 1991-06-04 Ciba-Geigy Corporation Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist
FR2663028B1 (fr) * 1990-06-08 1994-10-14 Roussel Uclaf Nouveaux derives de benzimidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
US5216003A (en) * 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
AU7275894A (en) * 1993-08-04 1995-02-28 Yamanouchi Pharmaceutical Co., Ltd. Imidazolylalkylamine derivative and pharmaceutical composition thereof
PL313769A1 (en) * 1993-09-30 1996-07-22 Yamanouchi Pharma Co Ltd Azole derivative and pharmaceutical composition thereof
MX9603316A (es) * 1994-02-18 1997-02-28 Janssen Pharmaceutica Nv (+)-liarozol enantiomericamente puro.
NZ279228A (en) * 1994-02-18 1997-11-24 Janssen Pharmaceutica Nv Laevorotarory imidazoyl-methyl benzimidazole derivatives (liarozole)
GB9418443D0 (en) * 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6696459B1 (en) 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
RU2191774C2 (ru) * 1994-12-22 2002-10-27 Лайджэнд Фармасьютикалз Инкорпорейтед Соединения-модуляторы стероидных рецепторов и способы
TW316902B (enExample) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
WO1996026927A1 (en) * 1995-03-01 1996-09-06 Yamanouchi Pharmaceutical Co., Ltd. Imidazole derivatives and medicinal composition thereof
US6288100B1 (en) * 1995-06-06 2001-09-11 American Home Products Corporation Benzimidazole derivatives
DE19535500A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Verfahren zur Herstellung von 3-Chlor-3'-nitro-4'-methoxybenzophenon
ATE303365T1 (de) * 1995-12-28 2005-09-15 Fujisawa Pharmaceutical Co Benzimidazolderivate
KR100365312B1 (ko) 1996-06-27 2003-03-06 얀센 파마슈티카 엔.브이. N-[4-(헤테로아릴메틸)페닐]헤테로아릴아민
FR2751649B1 (fr) * 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IT1286866B1 (it) * 1996-10-28 1998-07-17 Menarini Farma Ind Composti furano-eterociclici,loro preparazione ed uso come inibitori di aromatasi
AU730369B2 (en) * 1996-11-25 2001-03-08 Board Of Regents Of The University Of Nebraska, The Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
AU6229698A (en) 1997-02-21 1998-09-09 Takeda Chemical Industries Ltd. Fused ring compounds, process for producing the same and use thereof
TW453999B (en) 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
ATE270277T1 (de) 1997-12-11 2004-07-15 Janssen Pharmaceutica Nv Anilide als vitamin-a-säure-mimetika
DE19831985A1 (de) 1998-07-16 2000-01-20 Bayer Ag Substituierte Benzimidazole, ihre Herstellung und ihre Verwendung als Mittel gegen parasitäre Protozoen
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2375843A1 (en) * 1999-06-04 2000-12-14 Qi Zhao Compositions and methods for inhibiting cell death
HRP20020733A2 (en) 2000-03-16 2005-02-28 F. Hoffmann - La Roche Ag Carboxylic acid derivatives as ip antagonists
US7141598B2 (en) 2000-11-17 2006-11-28 Takeda Pharmaceutical Company, Ltd. Imidazole derivatives, production method thereof and use thereof
DE60144246D1 (de) 2000-11-20 2011-04-28 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
US7067537B2 (en) 2000-12-08 2006-06-27 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US6492517B1 (en) * 2001-07-19 2002-12-10 Air Products And Chemicals, Inc. Method for preparing halomethyl heterocyclic compounds
JP4634037B2 (ja) * 2001-11-16 2011-02-16 日本ケミファ株式会社 キサンチンオキシダーゼ阻害剤
AU2003291226B2 (en) * 2002-11-01 2009-06-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
JP2007500245A (ja) * 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
CA2562763A1 (en) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
JP4953455B2 (ja) * 2004-09-30 2012-06-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）として有用な新規なベンゾイミダゾール誘導体
CA2582356A1 (en) 2004-09-30 2006-04-13 Janssen Pharmaceutica N.V. Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
MY149459A (en) * 2006-01-24 2013-08-30 Janssen Pharmaceutica Nv Novel 2-substituted benzimidazoles as selective androgen receptor modulator (sarms)
AU2007215247B2 (en) 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
KR101307497B1 (ko) * 2006-04-19 2013-09-11 주식회사 동진쎄미켐 디이미다졸계 화합물 및 이를 이용한 유기발광소자
EP1992228A1 (en) * 2007-05-14 2008-11-19 Bayer CropScience AG Insecticidal substituted thiourea derivatives
AU2008256926B2 (en) * 2007-05-23 2013-09-19 Allergan, Inc. ((Bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
DE102009038950A1 (de) 2009-08-26 2011-03-03 Bayer Animal Health Gmbh Neue antiparasitäre Kombination von Wirkstoffen
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
WO2013049565A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Imidazole derivatives as cyp17 inhibitors for the treatment of cancer
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
KR101884447B1 (ko) * 2015-07-06 2018-08-01 삼성에스디아이 주식회사 모노머, 유기막 조성물, 유기막, 및 패턴형성방법
JP2024536342A (ja) * 2021-10-04 2024-10-04 ボルト バイオセラピューティクス、インコーポレーテッド 非対称ビス－ベンゾイミダゾールｓｔｉｎｇアゴニスト免疫複合体及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75101B (enExample) * 1980-10-23 1984-07-13 Pfizer
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
EP0178413A1 (en) * 1984-08-17 1986-04-23 Beecham Group Plc Benzimidazoles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100496308C (zh) * 2006-06-02 2009-06-10 上海烟草（集团）公司 造纸法再造烟叶半逆流多级萃取工艺

Also Published As

Publication number Publication date
KR880003935A (ko) 1988-06-01
HU198039B (en) 1989-07-28
NO873840L (no) 1988-03-16
GR3006841T3 (enExample) 1993-06-30
PH25022A (en) 1991-01-28
AU595064B2 (en) 1990-03-22
DK479487D0 (da) 1987-09-14
CA1323366C (en) 1993-10-19
CY1803A (en) 1987-09-09
IE60514B1 (en) 1994-07-27
DK174728B1 (da) 2003-10-06
FI87781B (fi) 1992-11-13
SU1662350A3 (ru) 1991-07-07
IE872487L (en) 1988-03-15
DK479487A (da) 1988-03-16
NO873840D0 (no) 1987-09-14
EP0260744A2 (en) 1988-03-23
FI873977A0 (fi) 1987-09-14
AU7838587A (en) 1988-04-14
EP0260744B1 (en) 1992-12-16
ES2053524T3 (es) 1994-08-01
PT85692A (en) 1987-10-01
KR960014353B1 (ko) 1996-10-15
IL83892A (en) 1991-11-21
JPS6485975A (en) 1989-03-30
NZ221729A (en) 1989-07-27
DE3783107D1 (de) 1993-01-28
IL83892A0 (en) 1988-02-29
DE3783107T2 (de) 1993-04-22
ZA876881B (en) 1989-04-26
HK123694A (en) 1994-11-18
FI873977A7 (fi) 1988-03-16
CN87106423A (zh) 1988-04-20
JPH0587071B2 (enExample) 1993-12-15
NO167202C (no) 1991-10-16
BG61321B2 (bg) 1997-05-30
NO167202B (no) 1991-07-08
EP0260744A3 (en) 1989-01-18
FI87781C (fi) 1993-02-25
HUT45051A (en) 1988-05-30
PT85692B (pt) 1990-06-29

Similar Documents

Publication Publication Date Title
CN1020903C (zh) 新颖的(1h-咪唑-1-基甲基)取代的苯并咪唑衍生物的制备方法
CN1022184C (zh) 制备(1h-唑-1-基甲基)取代的苯并三唑衍生物的方法
CN1033752C (zh) (1h-唑-1-基甲基)取代的喹啉或喹啉酮衍生物的制法
CN1171883C (zh) 非甾体抗炎药
CN1036263C (zh) 取代的唑类化合物的制备方法
CN1049654C (zh) 哌嗪衍生物及含其的药物组合物和用途
CN1152866C (zh) 苯并咪唑,其制法及其作为药物组合物的用途
CN1268133A (zh) 含有稠合环取代基的作为nos抑制剂的2－氨基吡啶
CN1281604C (zh) 取代吡唑化合物
CN1268626C (zh) 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物
CN87107539A (zh) 取代的碱性2-氨基-1，2，3，4-四氢化萘
HK1048994A1 (zh) 苯並二氮雜䓬衍生物、其製備和用途
CN1030252C (zh) 四氢苯并咪唑衍生物的制备方法
CN1976916A (zh) 选择的cgrp－拮抗剂，其制备方法以及它们作为药物的用途
CN1218471A (zh) 咔啉衍生物
CN1014790B (zh) 新型苯并唑基及苯并噻唑基胺类衍生物的制备方法及其应用
CN1678579A (zh) 吲哚－3－硫衍生物
CN1017242B (zh) 新的喹唑啉衍生物的制备方法
CN1720225A (zh) 具有5－羟色胺受体亲和性的n－芳基磺酰－3－取代吲哚及其制备方法和含有其的药物组合物
CN1427825A (zh) 吲哚满－2－酮衍生物、其制备方法及其作为催产素受体配体的应用
CN86105309A (zh) 作为消炎和镇痛药的1-取代的羟吲哚-3-碳酰胺类化合物
CN86108205A (zh) 新的噻唑化合物及其制备方法和它们的药物组合物
CN1745069A (zh) 用作ccr2受体拮抗剂的巯基咪唑
CN86107947A (zh) 新的头孢烯化合物及其制备方法
CN1079962A (zh) 新型取代叔胺化合物及其盐

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term